Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | GCLC | P48506 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | ARG2 | P78540 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buthionine Sulfoxime SCHEMBL9300391 | 1.00 | PMP22 (0.59) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| Buthionine Sulfoximine SCHEMBL62033 | 1.00 | PMP22 (0.59) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| Buthionine Sulfoxime SCHEMBL62034 | 1.00 | PMP22 (0.59) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| Buthionine Sulfoxime SCHEMBL4449935 | 1.00 | PMP22 (0.59) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| Buthionine Sulfoxime SCHEMBL121171 | 1.00 | PMP22 (0.59) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| Buthionine Sulfoximine SCHEMBL28249466 | 0.98 | PMP22 (0.58) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| SCHEMBL13746032 | 0.89 | PMP22 (0.63) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| SCHEMBL5904143 | 0.89 | PMP22 (0.63) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| SCHEMBL21965593 | 0.86 | PMP22 (0.50) | PMP22DDAH1GCLCSLC1A2SLC1A1 | |
| SCHEMBL27254997 | 0.86 | PMP22 (0.42) | PMP22DDAH1GCLCSLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065994-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | NICHENAMETLA SAILENDRA NATH (US) | 2024-02-29 | — | — | US | claimed |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2022-11-15 | — | — | US | claimed |
| US-20210386698-A1 | Compositions and Methods for Preventing or Treating Diseases or Disorders Associated with Protein Misfolding | NICHENAMETLA SAILENDRA NATH (US) | 2021-12-16 | — | — | US | claimed |
| US-20210003582-A1 | Method for Improving Quality of Therapeutic Cell Through Real-Time Glutathione Measurement | CELL2IN, INC. (KR) | 2021-01-07 | — | — | US | claimed |
| US-20200363422-A1 | Method for Measuring Quality of Therapeutic Cell Through Real-Time Glutathione Measurement | CELL2IN, INC. (KR) | 2020-11-19 | — | — | US | claimed |
| EP-3719500-A1 | METHOD FOR IMPROVING QUALITY OF THERAPEUTIC CELL THROUGH REAL-TIME GLUTATHIONE MEASUREMENT | Cell2in, Inc. (KR) | 2020-10-07 | — | — | EP | claimed |
| EP-3719501-A1 | METHOD FOR MEASURING QUALITY OF THERAPEUTIC CELL THROUGH REAL-TIME GLUTATHIONE MEASUREMENT | Cell2in, Inc. (KR) | 2020-10-07 | — | — | EP | claimed |
| EP-2064556-B1 | METHOD TO IDENTIFY AND TREAT SUBJECTS RESISTANT TO ACETYL SALICYLIC ACID | PULCINELLI FABIO MARIA (IT) | 2017-05-10 | — | — | EP | claimed |
| CN-101502484-B | Glucocorticosteroid and chemotherapy medicament carried by anticancer sustained-release agent | JINAN KANGQUAN PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-04-20 | — | — | CN | claimed |
| CN-1846676-A | Sustained-release injection containing fluorouracil synergist and preparation method thereof | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1736486-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-22 | — | — | CN | claimed |
| CN-1679952-A | Anticarcinogenic medicine composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1203894-C | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-06-01 | — | — | CN | claimed |
| CN-1203893-C | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-06-01 | — | — | CN | claimed |
| CN-1081033-C | Partial slow-released glutathione inhibitor | KONG QINGZHONG (CN) | 2002-03-20 | — | — | CN | claimed |
| CN-1326786-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2001-12-19 | — | — | CN | claimed |
| CN-1194829-A | Partial slow-released glutathione inhibitor | KONG QINGZHONG (CN) | 1998-10-07 | — | — | CN | claimed |
| US-5245077-A | Crystallization to separate the diastereoisomers | CORNELL RESEARCH FOUNDATION INC. (US) | 1993-09-14 | — | — | US | claimed |
| US-5171885-A | Pure stereoisomers of glutathione biosynthesis inhibitor | CORNELL RESEARCH FOUNDATION, INC. (US) | 1992-12-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | GGT1, GSR, GPX1 | PMP22 3262/4885DDAH1 1876/4885GCLC 9/4885 |
| US-20240065994-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | HSPA5, TXN2, TXNRD1 | PMP22 884/4885DDAH1 711/4885GCLC 25/4885 |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | GSR, GPX1, GGT1 | PMP22 2856/4885DDAH1 1715/4885GCLC 9/4885 |
| US-20210386698-A1 | Compositions and Methods for Preventing or Treating Diseases or Disorders Associated with Protein Misfolding | HSPA5, TXN2, TXNRD1 | PMP22 884/4885DDAH1 711/4885GCLC 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.